OncoMatch/Clinical Trials/NCT06625190
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Is NCT06625190 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Miltenyi CliniMACS Prodigy ® system and Zoledronic acid for neuroblastoma.
Treatment: Miltenyi CliniMACS Prodigy ® system · Zoledronic acid — Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for hematologic malignancies and non-malignant diseases additionally increasing the donor pool as to allow for haploidentical transplant to safely occur. While solid tumors can be highly chemotherapy sensitive, many remain resistant and require multimodalities of treatment. Immunotherapy has been developed to harness the immune system in fighting solid tumors, though not all have targeted effects. Some solid tumors are treated with autologous transplants; however, they do not always demonstrate an improved event free survival or overall survival. There has been evidence of the use of allogeneic stem cell transplants to provide a graft versus tumor effect, though studies remain limited. By utilizing αβ-T cell and B cell depletion for stem cell transplants and combining with zoledronic acid, the immune system may potentially be harnessed and enhanced to provide an improved graft versus tumor effect in relapsed/refractory solid tumors and promote an improved event-free survival and overall survival. This study will investigate the safety of treatment with a stem cell graft depleted of αβ-T cell and CD19+ B cells in combination with zoledronic acid in pediatric and young adult patients with select solid tumors, as well as whether this treatment improves survival rates in these patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroblastoma
Rhabdomyosarcoma
Sarcoma
Osteosarcoma
Demographics
Prior therapy
Must have received: autologous transplant
failed or deemed ineligible to receive autologous transplant or if autologous transplant did not offer >20% chance of cure
Cannot have received: allogeneic hematopoietic stem cell transplant
Exception: allowed if >6 months prior
Patients who have received an allogeneic HSCT within 6 months
Lab requirements
Kidney function
creatinine clearance or radioisotope gfr ≥60 ml/min/1.73 m2 or a serum creatinine based on age/gender
Cardiac function
ejection fraction of ≥ 40% by echocardiogram or radionuclide scan (muga)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Florida · Gainesville, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06625190 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic stem cell transplant disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 25 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages